Aligos Therapeutics (ALGS) Proxy Filing summary

Executive summary

• The annual meeting is scheduled for June 25, 2025, to be held virtually, with registration required by June 24, 2025.

• Five key proposals will be presented: election of three Class II directors, ratification of Ernst & Young LLP as auditor, amendment to the 2020 Incentive Award Plan, and amendments to increase authorized shares of both voting and non-voting common stock.

• The board recommends voting in favor of all proposals.

• Only stockholders as of April 28, 2025, are eligible to vote.

Voting matters and shareholder proposals

• Proposal 1: Elect three Class II directors to serve until the 2028 annual meeting.

• Proposal 2: Ratify Ernst & Young LLP as independent auditor for fiscal year ending December 31, 2025.

• Proposal 3: Approve an amendment to the 2020 Incentive Award Plan to add 1,000,000 shares.

• Proposal 4: Approve an amendment to increase authorized voting common stock from 20,000,000 to 100,000,000 shares.

• Proposal 5: Approve an amendment to increase authorized non-voting common stock from 800,000 to 15,800,000 shares.

• Shareholders may also vote on any other matters properly brought before the meeting.

Board of directors and corporate governance

• The board is divided into three classes with staggered three-year terms; seven directors currently serve.

• All directors except the CEO are considered independent under Nasdaq rules.

• The board has Audit, Compensation, and Nominating and Corporate Governance Committees, all composed of independent directors.

• The board’s leadership structure includes a lead independent director.

• The board encourages diversity of experience and background in director nominations.